skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Refine Results

Clear All


Show More


Show More

Show More


Show More

Show More

9 Total results for product and free and sample content found

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

J.P. Morgan Notebook Day 1: Pfizer, Gilead, Alnylam, Novartis, Sarepta, Deal Trends And Cell Therapy Challenges

11 Jun 2019

News and notes from the 2019 J.P. Morgan Healthcare Conference. Pfizer CEO Bourla underscores need for scientific and commercial innovation, Gilead makes M&A a priority, Novartis' new R&D chief reflects on first meeting with CEO Narasimhan, Sarepta CEO Ingram clarifies regulatory path for micro-dystrophin, J.P. Morgan outlines deal and macro biopharma trends in 2019, and cell therapy panel discusses manufacturing challenges.

Topic BioPharmaceutical Cell and gene therapy

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Gene Therapy: A Paradigm Shift in Medicine

10 Apr 2019

The following analysis reviews several aspects of the gene therapy market. The history of gene therapy is briefly discussed, alongside a look at the trend in the volume of candidates in development over the past 20+ years, and how the regulatory landscape in the US and EU has recently adapted to help move the field forward. A deep dive into the pipeline with  breakdowns by delivery method and therapy area is provided, as are the key companies involved and the major partnership deals that have made gene therapy a hot commodity. Manufacturing, pricing, and reimbursement issues are also addressed.

Topic Cell and gene therapy

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Bayer Bosses Beg Risk-Averse Europe To Rethink

07 Mar 2019

The German group believes it is going to be at the forefront of development in the cell and gene therapy space but is worried that Europe is failing to recognize the value that the pharma industry and its new technologies can create for society.

Topic cell-and-gene-therapy


Competitive Strategies Critical As EMA Decides On Kymriah And Yescarta

22 Aug 2018

With Novartis’s and Kite’s CAR T-cell therapies both expected to gain recommendations for pan-EU approval this week, discounts will need to be negotiated for these new treatments to reach the markets in Europe.

Topic cell-and-gene-therapy

Pink Sheet:世界の薬事規制と承認審査に関するニュース

CAR-T Therapy In Medicare: National Coverage Policy Could Come In 2019

18 May 2018

Medicare begins analysis process for CAR-T cancer therapies in response to a request from United Healthcare for a national coverage policy.

Topic Cancer Cell and gene therapy

Datamonitor Healthcare

Gene therapy

15 May 2018

Topic Cell and gene therapy

Datamonitor Healthcare

Tapping into the potential commercial success of cell and gene therapies

By Pharma Intelligence 16 Nov 2016

Financing and deal trends, and clinical expectations and reimbursement issues in the regenerative medicine

Topic cell-and-gene-therapy

Datamonitor Healthcare

Celgene opts in on Juno’s early-phase CAR-T therapies for $1bn upfront

By Zachary McLellan 02 Jul 2015

On 29 June 2015, Celgene and Juno Therapeutics announced a global collaboration for the development and commercialization of chimeric antigen receptor T cells (CAR-T) and T-cell receptor

Topic cell-and-gene-therapy


Recent Trends In Personalized Medicine

By Fern Barkalow 10 Mar 2014

To further encourage the use of biomarkers in clinical trials, the United States FDA issued additional biomarker guidance in August 2011 designed in part to help promote and harmonize biomarker development among regulatory agencies in the United States, European Union and Japan.

Topic clinical-trial-optimization cell-and-gene-therapy





電話:+81 (0)3 6273 4260